(rac)-Rivastigmine-d6(Synonyms: 利凡斯的明 d6)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
(rac)-Rivastigmine-d6 (Synonyms: 利凡斯的明 d6)

(Rac)-Rivastigmine-d6 ((Rac)-Rivastigmine-d6) 是 Rivastigmine 氘代消旋体。Rivastigmine (S-Rivastigmine) 是一种具有口服活性的，有效的胆碱酯酶 (ChE) 抑制剂，可抑制丁酰胆碱酯酶 (BChE) 和乙酰胆碱酯酶 (AChE)，IC50 分别为 0.037 μM 和 4.15 μM。Rivastigmine 可透过血脑屏障 (BBB)。Rivastigmine 是一种拟副交感神经剂或胆碱能剂，用于研究轻度至中度阿尔茨海默氏型痴呆和帕金森氏病引起的痴呆。

(rac)-Rivastigmine-d6(Synonyms: 利凡斯的明 d6)

(rac)-Rivastigmine-d6 Chemical Structure

CAS No. : 194930-04-6

规格 是否有货
1 mg Check price and availability
10 mg Check price and availability

* Please select Quantity before adding items.

生物活性

(Rac)-Rivastigmine-d6 ((Rac)-Rivastigmine-d6) is a labelled racemic Rivastigmine. Rivastigmine (S-Rivastigmine) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer’s type and dementia due to Parkinson’s disease[1][2].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

256.37

Formula

C14H16D6N2O2
CAS 号

194930-04-6
中文名称

利凡斯的明 d6
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Qian-Sheng Yu, et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. J Med Chem. 2002 Aug 15;45(17):3684-91.

    [3]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer’s disease. J Clin Neurol. 2011 Sep;7(3):137-42.

    [4]. Helena Shifrin, et al. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013;8(2):e57668.

    [5]. Raafat A Abdel-Aal, et al. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol. 2011 Jun 1;659(2-3):169-76.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务